Skip to main content

Table 2 Cox model distant relapse-free survival (DRFS) analyses in patients with residual disease from the MDACC-based cohort (GSE25066 [19])

From: Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy

    

Univariate analysis

Multivariable analysis

Variables

n

%

5-yr DRFS

HR

Lower 95 %

Upper 95 %

P value

HR

Lower 95 %

Upper 95 %

P value

Age, years (cont. variable)

1.0

0.98

1.01

0.590

0.98

0.97

1.01

0.129

Tumor size

           

 T0-T2

216

56 %

74 %

1.0

1.0

 T3-T4

173

44 %

61 %

2.1

1.38

3.07

<0.001

1.5

1.16

1.92

0.002

Node status

           

 N0

126

32 %

85 %

1.0

1.0

 N1-3

263

68 %

66 %

3.3

1.90

5.71

<0.001

2.9

1.62

5.37

<0.001

ER IHC

           

 Positive

129

34 %

78 %

1.0

1.0

 Negative

255

66 %

47 %

4.0

2.69

6.02

<0.001

1.8

0.87

3.56

0.114

PR IHC

           

 Positive

175

46 %

79 %

1.0

1.0

 Negative

208

54 %

54 %

3.3

2.15

5.05

<0.001

1.2

0.62

2.13

0.654

HER2 STATUS

           

 Negative

373

99 %

68 %

1.0

1.0

 Positive

3

1 %

NA

1.1

0.16

8.16

0.900

0.5

0.07

3.65

0.485

Histological grade

           

 1

28

8 %

96 %

1.0

1.0

 2

160

44 %

73 %

6.1

0.83

44.43

0.076

2.75

0.36

20.94

0.33

 3

175

48 %

60 %

10.9

1.51

78.73

0.018

2.54

0.33

19.66

0.37

PAM50

           

 Luminal A

144

37 %

83 %

1.0

1.0

 Luminal B

90

23 %

74 %

1.8

0.90

3.46

0.097

1.4

0.69

2.82

0.360

 HER2-E

30

8 %

41 %

5.9

3.38

10.30

<0.001

2.7

1.15

6.41

0.023

 Basal-like

102

26 %

48 %

5.3

2.63

10.84

<0.001

2.8

1.19

6.42

0.018

 Normal-like

23

6 %

82 %

1.6

0.55

4.85

0.380

  1. HER2-E, HER2-enriched; pCR, Pathological complete response; ER, Estrogen receptor; PR, Progesterone receptor; IHC, Immunohistochemistry